No - this analysis would explain why they may be shorting Neuren if what Little T had heard is correct. My point is that they clearly value Daybue poorly (incorrectly in my opinion) and IF they have a limited understanding of 2591s potential or just rarely put much weight on phase 2 assets then they would look at Neuren as overvalued and a short target. Unlike myself and others, no doubt, who think Neuren is undervalued
No - this analysis would explain why they may be shorting Neuren...
-
- There are more pages in this discussion • 333 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.14 |
Change
1.150(5.48%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $13.15M | 598.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 437 | $22.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.15 | 8325 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |